| Page 11 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Can JAK inhibition prevent GVHD?

In this issue of Blood, Pidala et al report on the results of a multicenter phase 2 trial, in which a

Therapy for acute myeloid leukemia in older and unfit adults

TITLE Azacitidine and venetoclax in previously untreated acute myeloid leukemia.

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe

Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

It is being increasingly recognized that many patients with blood cancers harbor germline variants that increase cancer risk.1 For example, 14% of patients with

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Author(s):

Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U

Primary Author:

Sekeres MA

Journal Title:

Leukemia & Lymphoma

Original Publication Date:

Nov 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists

Author(s):

Blankstein AR, Choi N, Mozessohn L, Sanford D, Paulson K, Rimmer E, Houston DS, Lother SA, Mendelson A, Garland A, Zarychanski R, Hay AE, Buckstein R, Houston BL

Primary Author:

Blankstein AR

Journal Title:

Annals of Hematology

Original Publication Date:

Nov 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Author(s):

Andritsos LA, McBride A, Tang D, Barghout V, Zanardo E, Song R, Huynh L, Yenikomshian M, Makinde AY, Hughes C, Hanna KS, Patel K

Primary Author:

Andritsos LA

Journal Title:

Leukemia Research

Original Publication Date:

Nov 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Author(s):

Papantoniou M, Stergiou I, Giannouli S, Bountziouka C, Kokotis P

Primary Author:

Papantoniou M

Journal Title:

British Journal of Haematology

Original Publication Date:

Nov 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Author(s):

Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM

Primary Author:

Bidikian A

Journal Title:

Expert Review of Anticancer Therapy

Original Publication Date:

Nov 2024

Introduction:

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

Author(s):

Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT,

Primary Author:

Komrokji RS

Journal Title:

Lancet Haematology

Original Publication Date:

Oct 2024

The WHO and International Consensus Classification 2022 classifications of

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)